This article will review these intersections of exercise and oncology, discuss the known mechanisms by which exercise exerts its salutary effects, and touch upon the future directions of exercise research in the oncology setting. Finally, recommendations are provided for clinicians to help patients with and without cancer take advantage of the benefits of physical activity.
• Exercise After Cancer Diagnosis: Time to Get Moving
• Physical Activity Across the Cancer Continuum

We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas.
• Molecular Classification of Diffuse Gliomas

Although the combination of CA-125 and HE4 appears indicated for use in symptomatic patients or in patients with an adnexal mass, there is no evidence that it would be indicated as a screening test in asymptomatic patients.

In this review, we discuss the discovery and biologic significance of HE4 and evaluate available evidence regarding the utility of HE4 as a biomarker for ovarian and endometrial cancer.
• HE4—Another Marker for Gynecologic Cancers: Do We Really Need One?
• HE4: Another ‘Player’ in the Epithelial Tumor Marker Arena?

The goals of care for patients with hormone receptor (HR)-positive advanced breast cancer include prolongation of disease-free and overall survival, amelioration of symptoms, and improvement in quality of life.

A considerable number of women with breast cancer are diagnosed during their reproductive years. In the short period of time in which newly diagnosed women will need to make decisions about surgical options and adjuvant therapy, younger women with breast cancer also face the potential impairment or complete loss of their fertility.
• Challenges and Opportunities
• Will Serial Reserve Screening Help?

The Case: A 48-year-old perimenopausal woman noted a lump in her left breast. She had had a mammogram 9 months earlier without abnormality. After ultrasound imaging confirmed a solitary mass measuring about 1.5 cm, a core needle biopsy demonstrated a poorly differentiated mammary carcinoma with chondroid features.

In my experience, being treated for low-volume Gleason 6 tumors is the norm, not the exception, for men in the United States. Surveillance may be discussed as an option, but it is not taken seriously.

The concept of active surveillance is based on the observation that Gleason 6 (pattern 3) prostate cancer is an indolent condition that poses little or no threat to the patient’s life. Conservative management is thus appropriate for these patients.

I looked after one of my partner’s patients who is approaching death from advanced, refractory ovarian cancer. She asked me not to talk about anything negative with her. We can’t really make any decisions without discussing negative things. Should I just remain silent about them at her request?

Nurses from a New Jersey cancer center have adapted several key plans from the CDC, ONS, and other societies to create a comprehensive infection-control plan.

In this interview, Laura Zitella will be discussing challenges and considerations for management and prevention of infection in the oncology setting—in both patients with solid tumors and those with hematologic malignancies.

A team of nurses and physicians from Huntsman Cancer Institute successfully implemented key changes in their Patient Acute Change Team that increased nurse involvement and reduced the number of codes by 90% in the outpatient setting since they were put in place 2 years ago.

Oncology nurses from a community hospital in Cincinnati, Ohio implemented a two-pronged process for the safe handling of chemotherapy, improving nurses’ satisfaction and comfort levels regarding chemotherapy safety.

This interview covers standards for healthcare provider competency in offering comprehensive genetic services, and highlights genetics/genomics resources for nurses.